GLP-1 Peptides Compared: Semaglutide vs Tirzepatide vs Liraglutide — Doses, Half-Lives & Reconstitution

Side-by-side research comparison of semaglutide, tirzepatide, liraglutide, and exenatide: receptor targets, half-lives, typical research doses, dosing frequency, and reconstitution math.

TL;DR

• GLP-1 peptides mimic incretin hormones to regulate appetite, gastric emptying, and glucose metabolism
• Semaglutide targets the GLP-1 receptor only and has a ~7-day half-life, enabling once-weekly dosing
• Tirzepatide is a GLP-1 + GIP dual agonist with enhanced efficacy in weight loss research compared to single agonists
• Liraglutide and Exenatide are earlier-generation GLP-1 agonists requiring daily or twice-daily dosing due to shorter half-lives
• Use the Dosage Calculator to plan your GLP-1 research protocol →

⚠️ Disclaimer: This article is written for educational and research purposes only. The compounds discussed here — semaglutide, tirzepatide, liraglutide, and exenatide — are prescription medications in most jurisdictions and/or research chemicals depending on form and source. Nothing in this article constitutes medical advice. Always consult a licensed healthcare professional before making any decisions related to these compounds.

The GLP-1 receptor agonist class has become one of the most scientifically significant areas in metabolic research over the past decade. Originally developed for type 2 diabetes management, these compounds have demonstrated substantial effects on body weight, cardiovascular risk markers, and even neurological outcomes in clinical and preclinical research. The underlying mechanism — mimicking the action of the naturally occurring incretin hormone glucagon-like peptide-1 — is shared across the class, but the four major research compounds differ considerably in their receptor targets, pharmacokinetics, and research dose profiles.

This guide presents a comprehensive side-by-side analysis of semaglutide, tirzepatide, liraglutide, and exenatide for researchers who need to understand the practical differences between these compounds when designing studies or interpreting the existing literature.

How GLP-1 Agonists Work

Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone secreted by L-cells in the distal small intestine and colon in response to food intake. It acts on GLP-1 receptors throughout the body — in the pancreas, brain, heart, kidneys, and gastrointestinal tract — to coordinate a set of physiologically integrated responses: enhanced glucose-dependent insulin secretion, suppressed glucagon release, slowed gastric emptying, and reduced appetite signaling through central hypothalamic pathways.

The major problem with native GLP-1 as a therapeutic or research tool is its extremely short half-life of 1–2 minutes in vivo, due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonists are engineered to resist this degradation, either through structural modifications that reduce DPP-4 access or through albumin binding (in the case of semaglutide) that dramatically extends circulating time.

All GLP-1 agonists share the core mechanism of glucose-dependent insulinotropic action — meaning they stimulate insulin release only when blood glucose is elevated, which substantially reduces the hypoglycemia risk seen with older antidiabetic compounds. This safety feature has made them attractive across multiple research domains beyond metabolic disease.

Compound Comparison Table

The Single Agonists: Semaglutide, Liraglutide, and Exenatide

Semaglutide is the most extensively studied GLP-1 single agonist and has become the reference compound for the entire class in recent years. Its extended half-life of approximately 7 days is achieved through two structural features: a C18 fatty diacid modification that enables albumin binding, and substitutions at positions 2 and 8 of the GLP-1 peptide sequence that block DPP-4 cleavage. In the SUSTAIN and STEP trial series, semaglutide at 2.4 mg weekly produced mean weight reductions of approximately 14.9% in adults with obesity, establishing it as a benchmark for weight loss efficacy in GLP-1 research.

For research applications, semaglutide is typically studied at doses escalating from 0.25 mg/week (initiation phase) up to 0.5, 1.0, 1.7, or 2.4 mg/week depending on the specific endpoint. The gradual escalation is standard protocol to manage gastrointestinal side effects including nausea and vomiting that are common during dose titration.

Liraglutide was the first once-daily GLP-1 agonist widely used in research and clinical practice. Its half-life of ~13 hours requires daily subcutaneous injection. At 3.0 mg/day (the dose studied in the SCALE trial series), liraglutide produced mean weight loss of approximately 8% at 56 weeks — less than semaglutide but still clinically meaningful. From a research standpoint, liraglutide's daily dosing frequency provides more granular control over exposure timing and makes it a useful tool for pharmacokinetic and mechanism studies where weekly dosing would obscure temporal relationships.

Exenatide in its standard form has the shortest half-life of the group at approximately 2.4 hours, requiring twice-daily injection. The extended-release (ER) formulation (Bydureon) encapsulates exenatide in microspheres that allow once-weekly dosing. Regular exenatide was historically significant as the first GLP-1 agonist approved for clinical use (2005), and it remains an important reference compound in the basic research literature. Doses of 5–10 mcg twice daily are typical in research protocols using the standard formulation.

The Dual Agonist: Tirzepatide

Tirzepatide represents the next generation of incretin-based research compounds. Rather than targeting only the GLP-1 receptor, tirzepatide is a dual agonist for both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is the other major incretin hormone, secreted by K-cells in the proximal small intestine, and it plays complementary roles in insulin secretion, adipose tissue metabolism, and energy homeostasis.

The pharmacological rationale for dual agonism is that GLP-1 and GIP act through partially overlapping but distinct pathways, and stimulating both simultaneously may produce synergistic effects beyond what either pathway can achieve alone. This hypothesis was dramatically validated in the SURMOUNT-1 phase 3 trial, where tirzepatide at 15 mg weekly produced a mean weight reduction of 22.5% — substantially greater than any GLP-1 single agonist in comparative trials. The 10 mg dose produced ~21.4% and the 5 mg dose ~16.0% mean weight loss at 72 weeks.

Structurally, tirzepatide is a 39-amino acid synthetic peptide based on the native GIP sequence with modifications enabling GLP-1 receptor co-agonism. It has a half-life of approximately 5 days — slightly shorter than semaglutide — but still supports once-weekly dosing. Research protocols typically follow an escalation schedule: 2.5 mg/week for 4 weeks, then 5 mg/week, advancing in 2.5 mg increments every 4 weeks as tolerated up to the target maintenance dose.

Triple Agonist Teaser: Retatrutide

The next frontier in GLP-1-based research is triple agonism: simultaneous targeting of the GLP-1, GIP, and glucagon receptors. Retatrutide, developed by Eli Lilly, is the leading triple agonist in clinical development. Early phase 2 data showed remarkable weight loss exceeding 24% at 48 weeks, potentially surpassing even tirzepatide. The addition of glucagon receptor agonism is thought to further enhance lipolysis and energy expenditure, though it introduces a more complex safety profile to manage.

For a detailed breakdown of retatrutide dosing and mechanism, see our dedicated guide: Retatrutide Dosage & Research Guide →

Reconstitution Math Differences: Weekly vs Daily Compounds

The dosing frequency of a GLP-1 compound has a direct impact on reconstitution math and how you track vial usage. The key difference between weekly and daily compounds is in vial longevity — how many doses a single reconstituted vial provides.

For weekly compounds (semaglutide, tirzepatide): A 5mg vial reconstituted in 2mL BAC water gives 2,500 mcg/mL. At a 2.5 mg/week dose, that's 1 mL per dose, and the vial lasts 2 weeks. At a 1 mg/week dose (1,000 mcg), you'd draw 0.4 mL per week, and the vial lasts 5 weeks. Weekly compoundsare far more forgiving on vial usage and reconstitution frequency.

For daily compounds (liraglutide): A 10mg vial reconstituted in 2mL gives 5,000 mcg/mL. At 1.8 mg/day (1,800 mcg), you'd draw 0.36 mL per day. The vial would last approximately 5–6 days — meaning you'll be reconstituting a new vial roughly weekly. This tighter consumption cycle requires careful planning of BAC water supply and vial inventory.

For twice-daily compounds (exenatide): At 10 mcg per dose (20 mcg/day), a 250 mcg/mL solution requires drawing only 0.04 mL per dose — a very small volume that requires either high-concentration reconstitution or careful use of low-volume syringes. Many researchers opt to reconstitute exenatide at higher concentrations (500–1,000 mcg/mL) to work with more measurable syringe volumes.

Use the Dosage Calculator → to plan your GLP-1 research protocol, including vial duration estimates based on your target dose and dosing frequency.

Which to Use for Which Research Question?

Selecting the appropriate GLP-1 compound for a research project depends on the specific question being investigated, the desired pharmacokinetic profile, and practical protocol design considerations.

For weight loss mechanism research where maximum efficacy is the priority, tirzepatide at its highest studied doses currently shows the strongest signal in the clinical literature. If you need a single-agonist comparator to isolate GLP-1 pathway effects, semaglutide at 2.4 mg/week provides the best-studied reference point.

For pharmacokinetic and timing studies where you need to manipulate exposure windows or study dose-response relationships at shorter timescales, liraglutide's daily dosing provides more experimental flexibility than weekly compounds. Exenatide's very short half-life (2.4 hours) makes it the best option for studies requiring rapid on/off kinetics.

For cardiovascular research, semaglutide has the largest body of cardiovascular outcome trial data (SUSTAIN-6, SELECT trials) making it the preferred reference compound for CV endpoints. Both semaglutide and liraglutide have demonstrated significant reductions in major adverse cardiovascular events (MACE) in their respective outcome trials.

For mechanistic dual-agonism studies, tirzepatide is the obvious choice, though interpretation requires care since separating GLP-1 and GIP contributions in vivo is methodologically challenging.

Conclusion

The GLP-1 peptide class spans a wide pharmacological range — from exenatide's rapid twice-daily kinetics to semaglutide's week-long half-life, and from simple single-target agonism to tirzepatide's dual receptor engagement. Understanding these differences is essential for designing well-controlled research protocols and for correctly interpreting data from this compound class. As the field moves toward triple agonists and novel combination approaches, the single and dual agonist compounds reviewed here will remain foundational reference points.

Use the dosage calculator to translate target doses into practical syringe volumes, and check the reconstitution calculator when setting up new vials to ensure your concentration math is correct from the start.

Frequently Asked Questions About GLP-1 Peptides

Q: What are GLP-1 peptides? A: GLP-1 peptides are compounds that mimic or enhance the action of glucagon-like peptide-1, a naturally occurring incretin hormone secreted by L-cells in the intestine after eating. They activate GLP-1 receptors throughout the body to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central hypothalamic signaling. Pharmaceutical GLP-1 agonists are engineered to resist rapid enzymatic degradation by DPP-4, which breaks down native GLP-1 in just 1–2 minutes.

Q: Which GLP-1 peptide causes the most weight loss? A: Based on current clinical trial data, Retatrutide (a triple GLP-1/GIP/glucagon agonist still under investigation) showed the highest mean weight loss at approximately 24.2% over 48 weeks. Among approved agents, tirzepatide at 15 mg/week produced approximately 22.5% mean weight loss in SURMOUNT-1, compared to semaglutide 2.4 mg/week which produced approximately 14.9% in STEP-1. Liraglutide and exenatide produce more modest weight loss of 5–8% in clinical trials.

Q: How does tirzepatide differ from semaglutide? A: Semaglutide is a pure GLP-1 receptor agonist, while tirzepatide is a dual agonist that activates both the GLP-1 and GIP receptors simultaneously. The additional GIP receptor activity enhances insulin secretion through a distinct signaling pathway, influences adipose tissue metabolism, and may upregulate GLP-1 receptor expression — together producing significantly greater weight loss than GLP-1 single agonism alone. Tirzepatide also has a slightly shorter half-life (~5 days vs. ~7 days for semaglutide) but both support once-weekly dosing.

Q: What is the half-life of semaglutide vs tirzepatide? A: Semaglutide has a half-life of approximately 7 days, achieved through a C18 fatty diacid modification that enables strong albumin binding and protects against DPP-4 cleavage. Tirzepatide has a half-life of approximately 5 days, also achieved via a C20 fatty diacid albumin-binding modification, though its GIP-derived backbone provides some intrinsic enzymatic stability as well. Both half-lives are long enough to support once-weekly subcutaneous dosing.

Q: Are GLP-1 peptides safe for research? A: In controlled clinical and research settings, GLP-1 receptor agonists have a well-characterized safety profile. The most common adverse events are gastrointestinal — nausea, vomiting, diarrhea, and constipation — which are most prevalent during dose escalation and typically subside over time. Structured dose escalation protocols exist specifically to minimize these effects. Rare but notable risks in the clinical literature include pancreatitis and, for the single-agonist class, a theoretical thyroid C-cell concern observed in rodents (not confirmed in human clinical data). All research use should comply with applicable institutional and regulatory guidelines.

This content is provided for educational and research informational purposes only. The compounds discussed are prescription medications or regulated research chemicals depending on jurisdiction. This article does not constitute medical advice, and nothing here should be interpreted as a recommendation to use these compounds outside of a licensed medical or research context.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions